Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics

Megna, Matteo; Potestio, Luca; Battista, Teresa; Camela, Elisa; Genco, Lucia; Noto, Matteo; Fabbrocini, Gabriella

doi:10.1111/ced.15395

Cited by 33 publications

(32 citation statements)

References 8 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 82%

“… 64 Moreover, no statistically significant differences in antibody titres between patients >55 years (426.3 ± 403.5 BAU/mL) and those aged <55 years (497.5 ± 437.0 BAU/mL) and between the different treatment groups in the psoriasis cohort were observed. 64 …”

Section: Resultsmentioning

confidence: 82%

“…Despite mean antibody titres being slightly higher in the healthy cohort (586.5 ± 408.3 BAU/mL vs 468.4 ± 420.3 BAU/ mL), no statistically significant differences were found between the study groups. 64 Moreover, no statistically significant differences in antibody titres between patients >55 years (426.3 ± 403.5 BAU/mL) and those aged <55 years (497.5 ± 437.0 BAU/mL) and between the different treatment groups in the psoriasis cohort were observed. 64 Finally, Cristaudo et al investigated the immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs on a cohort of 48 patients (anti-TNFα: 21; anti-IL17: 6; anti-IL12/23: 8: anti-IL23: 13) and 48 healthy controls.…”

Section: Resultsmentioning

confidence: 82%

“… 63 Similarly, Megna et al conducted a similar prospective study assessing blood samples 4 weeks (range 3–6 weeks) following the second dose of COVID‐19 vaccination with mRNA vaccines on 44 patients with psoriasis under biologics (anti-TNFα: 19; anti-IL17: 18; anti-IL12/23: 2: anti-IL23: 5). 64 A total of 57 subjects were enrolled in the healthy control group. 64 A positive antibody response was detected in 43 (97.7%) patients and 56 (98.2%) healthy subjects, with no significant difference between the groups.…”

Section: Resultsmentioning

confidence: 99%

“… 64 A total of 57 subjects were enrolled in the healthy control group. 64 A positive antibody response was detected in 43 (97.7%) patients and 56 (98.2%) healthy subjects, with no significant difference between the groups. Despite mean antibody titres being slightly higher in the healthy cohort (586.5 ± 408.3 BAU/mL vs 468.4 ± 420.3 BAU/mL), no statistically significant differences were found between the study groups.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Potestio¹,

Fabbrocini²,

Battista³

et al. 2023

PTT

Self Cite

View full text Add to dashboard Cite

The introduction of biologic drugs revolutionized the treatment of psoriasis, shifting treatment goals to higher treatment outcomes and less frequent safety issues. The outbreak of Coronavirus disease 2019 (COVID-19) represented a worldwide challenge, strongly affecting lifestyle, global economy, and overall health. Among the strategies adopted to contain the spreading of the infection, vaccination is the main one. In this context, the introduction of COVID-19 vaccines raised several doubts about their effectiveness and safety in patients undergoing therapy with biological for psoriasis. Even if molecular and cellular mechanisms by which COVID-19 vaccines lead to psoriasis development have not yet been fully elucidated, vaccination itself can trigger the release of interleukin (IL)-6, interferon (IFN) and tumor necrosis factor (TNF) α by T-helper (Th)1/Th17 cells. All these cytokines are involved in psoriasis pathogenesis. Thus, the aim of this manuscript is to review current literature on the safety and effectiveness of COVID-19 vaccination in psoriasis patients undergoing treatment with biologics, in order to clarify any concerns.

show abstract

Section: Resultsmentioning

confidence: 82%

Section: Resultsmentioning

confidence: 82%

Section: Resultsmentioning

confidence: 82%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Potestio¹,

Fabbrocini²,

Battista³

et al. 2023

PTT

Self Cite

View full text Add to dashboard Cite

show abstract

Management of Psoriasis Patients with Serious Infectious Diseases

Megna,

Lauletta,

Tommasino

et al. 2024

Adv Ther

Self Cite

View full text Add to dashboard Cite

The management of patients affected by moderate-to-severe psoriasis may be challenging, in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C, HIV, COVID-19]. Indeed, these infections should be ruled out before starting and during systemic treatment for psoriasis. Currently, four conventional systemic drugs (methotrexate, dimethyl fumarate, acitretin, cyclosporine), four classes of biologics (anti-tumour necrosis factor alpha, anti-interleukin (IL)12/23, anti-IL-17s, and anti-IL-23], and two oral small molecules (apremilast, deucravacitinib) have been licensed for the treatment of moderate-to-severe psoriasis. Each of these drugs is characterized by a unique safety profile which should be considered before starting therapy. Indeed, some comorbidities or risk factors may limit their use. In this context, the aim of this manuscript was to evaluate the management of patients affected by moderate-to-severe psoriasis with serious infectious diseases.

show abstract

The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review

Potestio,

Tommasino,

Lauletta

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics

Cited by 33 publications

References 8 publications

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Management of Psoriasis Patients with Serious Infectious Diseases

The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review

Contact Info

Product

Resources

About